Olema Pharmaceuticals Inc... (OLMA)
5.33
0.19 (3.70%)
At close: Jan 15, 2025, 11:14 AM
Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers.
Its lead product candidate is OP-1250, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
Olema Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Nov 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 74 |
| CEO | Dr. Sean P. Bohen M.D., Ph.D. |
Contact Details
Address: 512 2nd Street San Francisco, California United States | |
| Website | https://www.olema.com |
Stock Details
| Ticker Symbol | OLMA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001750284 |
| CUSIP Number | 68062P106 |
| ISIN Number | US68062P1066 |
| Employer ID | 30-0409740 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | President, Chief Executive Officer & Director |
| Courtney O'Konek | Vice President of Corporate Communications |
| Dr. David C. Myles Ph.D. | Chief Discovery & Non-Clinical Development Officer |
| Dr. Naseem Zojwalla M.D. | Chief Medical Officer |
| Julie Dexter | Senior Vice President & Head of People |
| Sasha Austin CPA | Vice President of Finance & Controller |
| Shane William Charles Kovacs M.B.A. | Chief Operating & Financial Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jan 14, 2025 | 4 | Filing |
| Jan 13, 2025 | 4 | Filing |
| Jan 13, 2025 | 3 | Filing |
| Jan 13, 2025 | SCHEDULE 13G/A | [Amend] Filing |
| Jan 13, 2025 | 8-K | Current Report |
| Jan 10, 2025 | 8-K | Current Report |
| Jan 06, 2025 | S-3 | Filing |
| Jan 03, 2025 | S-3 | Filing |
| Dec 18, 2024 | 4/A | [Amend] Filing |
| Dec 17, 2024 | 4 | Filing |